Arndt Vogel/X
May 17, 2024, 16:09
Trastuzumab deruxtecan in HER2+ gastric cancer overviewed by Arndt Vogel
Arndt Vogel, managing senior consultant and professor in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, shared a post on X:
“Trastuzumab deruxtecan in HER2+ gastric cancer
exploratory biomarker analysis of DESTINY Gastric01
64% concordance btw HER2+ IHC and blood
MET, EGFR and FGFR2 GA: ORR low
HER2 mutations: ORR high
activity in Her2 low.”
Read further.
Source: Arndt Vogel/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 18, 2024, 11:13
Nov 18, 2024, 09:58
Nov 18, 2024, 09:34
Nov 18, 2024, 08:33
Nov 18, 2024, 08:00
Nov 18, 2024, 07:30
Nov 18, 2024, 07:20